ConductScience.org, home

Paper41979035

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Azad AA and 10 others. Future Oncol, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. Papers, record 41979035. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41979035

Download JSON
Disease
prostate cancer757 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.
PubMed
Journal
Future Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Azad AAArun Ahttps://orcid.org/0000-0001-7350-5622
2Agarwal NNeeraj
3Armstrong AJAndrew J
4Hellmis EEva
5Sugimoto MMikio
6Ürün YYüksel
7Xing NNianzeng
8Aregay MMehreteab
9Lima JJulianne
10Meulendijks DDidier
11Chi KNKim Nhttps://orcid.org/0000-0002-3782-7226

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Androgen Receptor AntagonistsMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Prostatic NeoplasmsMajor topic
Humans
Male
Benzamides
Double-Blind Method
Poly(ADP-ribose) Polymerase Inhibitors
Receptors, Androgen

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06120491Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131157964Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med2019https://conductscience.org/library/papers/31157964PubMed
226903579Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.J Clin Oncol2016https://conductscience.org/library/papers/26903579PubMed
333993099Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease.Transl Oncol2021https://conductscience.org/library/papers/33993099PubMed
440683290Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.Lancet2025https://conductscience.org/library/papers/40683290PubMed
534328216Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study.Cancer2021https://conductscience.org/library/papers/34328216PubMed
632169995Long-term Trends in Prostate Cancer Incidence by Stage at Diagnosis in Japan Using the Multiple Imputation Approach, 1993-2014.Cancer Epidemiol Biomarkers Prev2020https://conductscience.org/library/papers/32169995PubMed
741064809Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.NAR Cancer2025https://conductscience.org/library/papers/41064809PubMed
835929986Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.Clin Cancer Res2022https://conductscience.org/library/papers/35929986PubMed
919097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1028851861Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.Nat Commun2017https://conductscience.org/library/papers/28851861PubMed
1127989354Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.Eur Urol2017https://conductscience.org/library/papers/27989354PubMed
1241057655Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.Nat Med2025https://conductscience.org/library/papers/41057655PubMed
1332955174Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.N Engl J Med2020https://conductscience.org/library/papers/32955174PubMed
1441591905Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41591905PubMed
1534759656High rates of advanced prostate cancer in the Middle East: Analysis from a tertiary care center.Urol Ann2021https://conductscience.org/library/papers/34759656PubMed
1637963304Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.J Clin Oncol2024https://conductscience.org/library/papers/37963304PubMed
1725601341
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Lancet Oncol2015https://conductscience.org/library/papers/25601341PubMed
1838572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
1928536297Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.Sci Signal2017https://conductscience.org/library/papers/28536297PubMed
2029367197Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.Cancer Discov2018https://conductscience.org/library/papers/29367197PubMed

See all 60 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42568603From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.Front Oncol2026https://conductscience.org/library/papers/42568603

Source PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AR367PubTator's text mininghttps://conductscience.org/library/genes/367NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
SARUPARIBCHEMBL5095220Derived from the trial1https://conductscience.org/library/drugs/CHEMBL5095220

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41979035

GET https://conductscience.org/api/papers/v1/41979035/references?page=2